ARH-77 Xenograft Model Service for Leukemia

The ARH-77 cell line offers a specialized in vivo platform frequently utilized for studying plasma cell dyscrasias and serving as a comparative model for multiple myeloma and related leukemia research. As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision ARH-77 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your hematological drug discovery and development pipeline.

Overview of ARH-77 Xenograft Model for Leukemia

The ARH-77 xenograft model is an established in vivo translational system widely used in hematological research to study plasma cell disorders. Originally derived from a patient with plasma cell leukemia, the ARH-77 cell line exhibits a mature B-cell phenotype and is often employed as a reference model for assessing the biology of plasma cell-related malignancies and the behavior of B-cell lineages in an immunodeficient host.

Biologically, the ARH-77 model is valued for its capacity to engraft in immunodeficient mice, providing investigators with a platform to examine the interactions between human plasma-like cells and the in vivo microenvironment. This model is particularly useful for pre-clinical studies focusing on cell surface marker dynamics, monoclonal antibody targeting, and the evaluation of therapeutic agents designed to modulate B-cell or plasma cell-related pathways. By providing a stable in vivo environment, the ARH-77 model allows for the systematic investigation of compound efficacy and pharmacodynamics in a physiologically relevant model system.

Cell Line Information: ARH-77

The ARH-77 cell line originated from a patient diagnosed with plasma cell leukemia. While its precise molecular origins have been studied extensively, it serves as a robust proxy for research involving B-cell/plasma cell biology and is widely utilized in comparative oncological studies.

Our Services

Workflow of ARH-77 Xenograft Model Construction

• Cell Culture & Quality Control: Human ARH-77 cells are expanded in vitro using certified nutrient suspension media under optimized growth parameters. STR authentication and mycoplasma clearance verification are completed prior to inoculation to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunodeficient mice (e.g., NSG or NOD/SCID strains) are sourced from validated vendors. The animals undergo a dedicated acclimatization phase to stabilize baseline biological and physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability ARH-77 cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into the host cohorts, typically via subcutaneous or intravenous routes, depending on the specific research objective (e.g., localized tumor formation vs. systemic dissemination).
• Longitudinal Growth Tracking: Following inoculation, disease progression or tumor development is systematically monitored. For systemic models, FACS is used to detect human CD45+ or CD138+ cells; for solid tumor models, calipers are used for volume measurement.
• Stratification & Dosing: Once disease burden reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts to ensure balanced baseline dimensions before the initiation of customized therapeutic dosing regimens.

Fig 1. ARH-77 Xenograft Model Construction Workflow

Case Study - ARH-77 Xenograft Model Development

A pre-clinical validation study was conducted using the ARH-77 xenograft model to evaluate the therapeutic efficacy of a novel agent targeting B-cell lineage markers. Following precision inoculation of human ARH-77 cells into immunodeficient mice, the animals exhibited consistent engraftment and growth patterns across all study cohorts. Animals assigned to the active treatment group demonstrated a clear, statistically significant reduction in tumor burden and/or circulating cell populations compared to the vehicle control, confirming the model's sensitivity and reliability for assessing novel therapeutic candidates in a plasma-cell-related research context.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse hematological and plasma cell lineages, providing highly reproducible in vivo translational platforms.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive metrics and robust statistical validations.

Contact us

Accelerating your leukemia or plasma cell dyscrasia research pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our ARH-77 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.